​

Recursion Pharmaceuticals (RXRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RXRX Stock Forecast

Recursion Pharmaceuticals (RXRX) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $9.67, with a high of $12.00 and a low of $6.00. This represents a 35.06% increase from the last price of $7.16.

$6 $7 $8 $9 $10 $11 $12 $13 $14 High: $12 Avg: $9.67 Low: $6 Last Closed Price: $7.16

RXRX Stock Rating

Recursion Pharmaceuticals stock's rating consensus is Hold, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (20.00%), 4 Hold (80.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 5 0 4 1 Strong Sell Sell Hold Buy Strong Buy

RXRX Forecast vs Benchmarks

TypeNameUpside
StockRecursion Pharmaceuticals35.06%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$11.25
Last Closing Price$7.16$7.16$7.16
Upside/Downside--57.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25116--8
Dec, 24116--8
Nov, 24126--9
Oct, 24126--9
Sep, 24126--9
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 04, 2024Gil BlumNeedham$11.00$6.1080.33%53.63%
Sep 03, 2024Scott SchoenhausKeyBanc$12.00$6.0797.69%67.60%
Sep 03, 2024Dennis DingJefferies$6.00$6.02-0.33%-16.20%
Jun 26, 2024Scott SchoenhausKeyBanc$16.00$8.7682.65%123.46%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Sep 04, 2024NeedhamMarket PerformMarket Performhold
Sep 04, 2024NeedhamBuyBuyhold
Sep 03, 2024KeyBancOverweightOverweighthold
Sep 03, 2024Cowen & Co.HoldHoldhold
Sep 03, 2024JefferiesHoldHoldhold
Jun 26, 2024KeyBancOverweightOverweighthold
May 10, 2024NeedhamBuyBuyhold
Apr 09, 2024NeedhamBuyBuyhold
Mar 04, 2024NeedhamBuyBuyhold
Jan 17, 2024NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.42$-1.36$-1.58-----
Avg Forecast$-1.19$-1.41$-1.65$-1.54$-1.65$-1.38$-1.12$-0.95
High Forecast$-2.42$-2.57$-1.73$-1.63$-1.85$-2.85$-2.32$-1.97
Low Forecast$-0.39$-0.42$-1.59$-1.45$-1.49$-0.17$-0.14$-0.12
Surprise %19.33%-3.55%-4.24%-----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.00M$39.68M$44.58M-----
Avg Forecast$12.32M$48.26M$52.14M$70.75M$92.56M$123.79M$143.40M$194.30M
High Forecast$5.98M$22.19M$43.58M$63.61M$44.06M$40.35M$46.74M$63.33M
Low Forecast$22.09M$78.87M$60.00M$85.45M$147.23M$225.66M$261.40M$354.19M
Surprise %-18.86%-17.78%-14.51%-----

Net Income Forecast

$-600M $-480M $-360M $-240M $-120M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-178.07M$-239.42M$-328.07M-----
Avg Forecast$-247.35M$-292.38M$-344.74M$-319.83M$-346.84M$-347.15M$-232.80M$-197.46M
High Forecast$-502.09M$-533.44M$-359.02M$-338.17M$-384.31M$-592.26M$-481.84M$-408.70M
Low Forecast$-81.84M$-87.01M$-330.46M$-301.50M$-309.38M$-35.40M$-28.80M$-24.43M
Surprise %-28.01%-18.11%-4.84%-----

RXRX Forecast FAQ

Is Recursion Pharmaceuticals stock a buy?

Recursion Pharmaceuticals stock has a consensus rating of Hold, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Recursion Pharmaceuticals is a neutral investment for most analysts.

What is Recursion Pharmaceuticals's price target?

Recursion Pharmaceuticals's price target, set by 5 Wall Street analysts, averages $9.67 over the next 12 months. The price target range spans from $6 at the low end to $12 at the high end, suggesting a potential 35.06% change from the previous close price of $7.16.

How does Recursion Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

Recursion Pharmaceuticals stock forecast shows a 35.06% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Recursion Pharmaceuticals over the past three months?

  • January 2025: 12.50% Strong Buy, 12.50% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 12.50% Strong Buy, 12.50% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 11.11% Strong Buy, 22.22% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is Recursion Pharmaceuticals’s EPS forecast?

Recursion Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is -1.54 for 2024, a -2.53% decrease from the reported $-1.58 in 2023. The prediction for 2025 is $-1.65, $-1.38 for 2026, $-1.12 for 2027, and $-0.95 for 2028.

What is Recursion Pharmaceuticals’s revenue forecast?

Recursion Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $70.75M for 2024, a 58.72% increase from the reported $44.58M in 2023. The forecast for 2025 is $92.56M, $123.79M for 2026, $143.4M for 2027, and $194.3M for 2028.

What is Recursion Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, Recursion Pharmaceuticals's average annual net income forecast is $-320M for 2024, reflecting a -2.51% decrease from the reported $-328M in 2023. The projection for 2025 is $-347M, $-347M for 2026, $-233M for 2027, and $-197M for 2028.